ValuEngine downgraded shares of NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) from a sell rating to a strong sell rating in a research note issued to investors on Friday.
NBY has been the subject of a number of other research reports. Maxim Group reiterated a hold rating on shares of NovaBay Pharmaceuticals in a research note on Friday, August 11th. HC Wainwright set a $6.00 price target on NovaBay Pharmaceuticals and gave the company a buy rating in a research note on Friday, August 11th. Zacks Investment Research upgraded NovaBay Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, August 16th. Finally, Roth Capital set a $5.00 target price on NovaBay Pharmaceuticals and gave the stock a buy rating in a research note on Monday, October 23rd. Two analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus price target of $6.40.
Shares of NovaBay Pharmaceuticals (NBY) opened at $4.19 on Friday. NovaBay Pharmaceuticals has a 12-month low of $2.25 and a 12-month high of $5.00.
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for NovaBay Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.